Wanbury Limited — Important, 12-02-2025: Financial Result Updates

**Wanbury Limited - Financial Summary**

Consolidated financial results show a total revenue of ₹134.29 crore for the quarter ended December 31, 2024, representing an increase of 7.67% year-over-year. The growth can be attributed to enhanced demand in the pharmaceuticals sector and operational improvements despite a 30-day shutdown for facility upgrades during the quarter.

Net profit stood at ₹12.18 crore, down 84.74% compared to ₹78.05 crore in the prior year. This decline underscores the impact of operational costs rising by 13.22%, totaling ₹132.99 crore, primarily driven by increased raw material prices and employee benefits expenses.

The company’s Earnings Per Share (EPS) has dipped to ₹0.38 from ₹2.44 a year earlier, reflecting this sharp rise in costs.

Furthermore, the balance sheet indicates potential liquidity pressure, with current liabilities surpassing current assets; however, the management emphasizes ongoing measures to address these challenges and maintain operations effectively.

In strategic terms, Wanbury's management is focused on debt restructuring and maintaining cost efficiency to drive future profitability. The market sentiment appears cautious, making it a pivotal time for investor assessment.

Given the current operational challenges alongside the potential for recovery as the facilities ramp back up, a hold position may be prudent as investors assess the turnaround strategies implemented by management moving forward.